# Sigma Bio's CTO describes organoid-plus-AI drug discovery a year after Galien nomination

> Original title: 盖伦奖提名一年后，希格生科的边界、验证与野心

- Source: Leiphone
- Published: 2026-10-30T10:03:00.000Z
- Bad Influence: https://badinfluence.news/items/yia9la3isr1w81iagnoojezg9
- Original: https://www.leiphone.com/category/aihealth/BseLhlDzaWQ8XrWr.html

## Summary

Sigma Bio CTO Zhuo Zhuo says the company's SIGX1094 candidate for diffuse gastric cancer is in clinical trials, and it has received orphan drug and fast-track designations in the US. Zhuo says the company's organoid-plus-AI platform, built with XtalPi, feeds experimental efficacy and safety data back into AI molecule design. He also says China's drug regulator is validating organoids as an alternative to animal testing, and Sigma Bio is the only company among seven participating institutions.

## Why it matters

The interview shows how Sigma Bio's organoid-plus-AI model connects molecule design, synthesis and tissue testing, and how regulators are moving to accept organoid data.